TIAA CREF Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

TIAA CREF Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-350	Closed	-$120K	–	3191
2017 Q1	$120K	Hold	350	–	–	﹤0.01%	3032
2016 Q4	$122K	Sell	350 -10	-3%	-$3.66K	﹤0.01%	3075
2016 Q3	$144	Hold	360	–	–	﹤0.01%	3075
2016 Q2	$214K	Buy	+360	New	+$219K	﹤0.01%	3084
2014 Q2	–	Sell	-48	Closed	-$256K	–	3187
2014 Q1	$256K	Buy	+48	New	+$227K	﹤0.01%	3057

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

TIAA CREF Investment Management's EIGR Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2017, closing a stake of 350 shares — an estimated $120K sold.

TIAA CREF Investment Management first reported a position in EIGR in Q1 2014 and held it in 5 quarters. The position peaked at $256K in Q1 2014. 39 funds tracked by Wall St. Rank hold EIGR as of Q2 2017.

TIAA CREF Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
TIAA CREF Investment Management sold 350 Eiger BioPharmaceuticals, Inc. shares in Q2 2017, an estimated $120K.
TIAA CREF Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
TIAA CREF Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $256K in Q1 2014.
39 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.